Further evidence on the anxiogenic-like effect of substance P evaluated in the elevated plus-maze in rats

Behavioural Brain Research

Volumn 154, Issue 2, 2004, Pages 501-510

  Duarte, Filipe S ^a   Testolin, Raquel ^a   De Lima, Thereza C M ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Anxiety; Enzymatic cleavage; NK receptors; Plus maze; Tachykinins

Indexed keywords

ANXIOLYTIC AGENT; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; PHOSPHORAMIDON; SAREDUTANT; SUBSTANCE P; SUBSTANCE P DERIVATIVE; THIORPHAN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENZYME DEGRADATION; FRAGMENTATION REACTION; INTERMETHOD COMPARISON; MALE; MAZE TEST; NEUROCHEMISTRY; NEUROPHARMACOLOGY; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZAMIDES; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLYCOPEPTIDES; INDOLES; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MICROINJECTIONS; MOTOR ACTIVITY; PEPTIDE FRAGMENTS; PIPERIDINES; PROTEASE INHIBITORS; PYRROLIDONECARBOXYLIC ACID; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; SUBSTANCE P; THIORPHAN; TIME FACTORS;

EID: 4143105582     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2004.03.020     Document Type: Article

References (66)

1. Aguiar M.S., Brandão M.L. Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test. Physiol. Behav. 60(4):1996;1183-1186
2. Archer J. Tests for emotionality in rats and mice: a review. Anim. Behav. 21(2):1973;205-235
3. Bertoglio L.J., Carobrez A.P. Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav. Brain Res. 108(2):2000;197-203
4. Bondy B., Baghai T.C., Minov C., Schule C., Schwarz M.J., Zwanzger P., et al. Substance P serum levels are increased in major depression: preliminary results. Biol. Psychiatry. 53(6):2003;538-542
5. Bourne A., Barres K., Taylor B.A., Turner A.J., Kenny A.J. Membrane peptidases in the pig choroid plexus and on other cell surfaces in contact with the cerebrospinal fluid. Biochem. J. 259:1989;69-80
6. Cascieri MA, Huang RRC, Fong TM, Cheung AH, Sadowski S, Ber E, et al. Determination of the amino acid residues in substance P conferring selectivity and specificity for the rat neurokinin receptors. Mol Pharmacol 1992;41(6):1096-9.
7. Cole J.C., Rodgers R.J. Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol. Biochem. Behav. 52:1994;473-478
8. Conlon J.M., Goke B. Metabolism of substance P in human plasma and in the rat circulation. J. Chromatogr. 296:1984;241-247
9. Couture R., Regoli D. Inactivation of substance P and its C-terminal fragments in rat plasma and its inhibition by Captopril. Can. J. Physiol. Pharmacol. 59(6):1981;621-625
10. De Araújo J.E., Huston J.P., Brandão M.L. Aversive effects of the C-fragment of substance P in the dorsal periaqueductal gray matter. Exp. Brain Res. 123:1998;84-89
11. De Araújo J.E., Silva R.C.B., Huston J.P., Brandão M.L. Anxiogenic effects of substance P and its 7-11 C terminal, but not the 1-7 N terminal, injected into the dorsal periaqueductal gray. Peptides. 20:1999;1437-1443
12. De Araújo J.E., Huston J.P., Brandão M.L. Opposite effects of substance P fragments C (anxiogenic) and N (anxiolytic) injected into dorsal periaqueductal gray. Eur. J. Pharmacol. 432(1):2001;43-51
13. File S.E. Anxiolytic action of a neurokinin 1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav. 58:1997;747-752
14. 1 receptor antagonist, has an anxiolytic action in the social interaction test in rats. Psychopharmacology (Berl.). 152(1):2000;105-109
15. 1 receptor antagonist, FK 888. Br. J. Pharmacol. 107:1992;785-789
16. Gavioli E.C., Canteras N.S., De Lima T.C. Anxiogenic-like effect induced by substance P injected into the lateral septal nucleus. Neuroreport. 10(16):1999;3399-3403
17. 1 receptors in mediating anxiogenic effects induced by intracerebroventricular injection of substance P. Behav. Brain Res. 134(1/2):2002;411-415
18. Gray JA. The neuropsychology of anxiety: an enquire into the functions of the septo-hippocampal system. Oxford: Claredon Press; 1982.
19. Hall M.E., Stewart J.M. Modulation of isolation-induced fighting by N- and C-terminal analogs of substance P: evidence for multiple recognition sites. Peptides. 5:1984;85-89
20. Hall M.E., Grantham P., Limoli J., Stewart J.M. Effects of substance P and neurokinin A (substance K) on motor behavior: unique effect of substance P attributable to its amino-terminal sequence. Brain Res. 420:1987a;82-94
21. Hall ME, De Armey P, Stewart JM. Effects of an amino-terminal fragment of substance P on brain dopamine and serotonin metabolism. In: Henry JL, Couture R, Cuello AC, Pelletier G, Quirion R, Regoli D, editors. Substance P and neurokinins. Berlin, Heidelberg, New York: Springer; 1987b. p. 344-6.
22. Hall M.E., Stewart J.M. The substance P fragment SP (1-7) stimulates motor behavior and nigral dopamine release. Pharmacol. Biochem. Behav. 41:1992;75-78
23. Hasenöhrl R.U., De Souza Silva M.A., Nikolaus C., Tomaz C., Brandão M.L., Schwarting R.K.W., et al. Substance P and its role in neural mechanisms governing learning. Neuropeptides. 34(5):2000;272-280
24. Herrera-Marschitz M., Terenius L., Sakurada T., Reid M.S., Ungersted U. The substance P (1-7) fragment is a potent modulator of substance P actions in the brain. Brain Res. 521:1990;316
25. Hooper N.M., Turner A.J. Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism. Biochem. J. 241:1987;625-633
26. Huston J.P., Hasenöhrl R.U., Boix F., Gerhardt P., Schwarting R.K. Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity. Psychopharmacology (Berl.). 112(2/3):1993;147-162
27. Igwe O.J., Felice L.J., Seybold V.S., Larson A.A. Optimization of high-performance liquid chromatography-radioimmunoassay protocols for the analyses of substance P and some of its metabolic fragments. J. Chromatogr. 432:1988;113-126
28. Igwe O.J., Sun X., Larson A.A. Role of substance P amino terminal metabolites in substance P-induced desensitization in mice. Neuroscience. 36(2):1990;535-542
29. Kostel K.L., Lunte S.M. Evaluation of capillary electrophoresis with post-column derivatization and laser-induced fluorescence detection for the determination of substance P and its metabolites. J. Chromatogr. B Biomed. Sci. Appl. 695(1):1997;27-38
30. Kramer M.S., Cutler N., Feigner F., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science. 281:1998;1640-1645
31. Krause JE. On the physiological metabolism of substance P. In: Jordan CC, Oehme P, editors. Substance P: metabolism and biological actions. London: Taylor and Francis; 1985. p. 13-31.
32. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl.). 92:1987;180-185
33. Lister R.G. Ethological-based animal models of anxiety disorders. Pharmacol. Ther. 46:1990;321-340
34. Liu H., Cao Y., Basbaum A.L., Mazarati A.M., Sankar R., Wasterlain C.G. Resistence to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc. Natl. Acad. Sci. 96:1999a;12096-12101
35. Liu H., Mazarati A.M., Katsumori H., Sankar R., Wasterlain C.G. Substance P is expressed in hippocampal principal neurons during status epilepticus, and plays a critical role in the maintenance of status epilepticus. Proc. Natl. Acad. Sci. 96:1999b;5286-5291
36. Mauborgne A., Javoy-Agid F., Legrand J.C., Agid Y., Cesselin F. Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains. Brain Res. 268(1):1983;167-170
37. Millan M.J. The neurobiology and control of anxious states. Prog. Neurobiol. 70:2003;83-244
38. Nikolaus S., Huston J.P., Hasenöhrl R.U. Anxiolytic-like effects in rats produced by ventral pallidal injection of both N- and C-terminal fragments of substance P. Neurosci. Lett. 283:2000;37-40
39. Otsuka M., Yoshioka L. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 73:1993;229-308
40. Paxinos G, Watson C. The rat brain: in stereotaxic coordinates, 2nd ed. Australia: Academic Press Inc.; 1986.
41. Pellow S., Chopin P., File S., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in rat. J. Neurosci. Meth. 14:1985;149-167
42. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24(3):1986;525-529
43. Persson S., Le Grevés P., Thörnwall M., Eriksson U., Silberring J., Nyberg F. Neuropeptide converting and processing enzymes in the spinal cord and cerebrospinal fluid. Progr. Brain Res. 104:1995;11-130
44. Probert L., Hanley M.N. The immunocytochemical localization of substance P-degrading enzyme within the rat spinal cord. Neurosci. Lett. 78:1987;132-137
45. Raffa R.B. Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Neurosci. Biobehav. Rev. 22:1998;789-813
46. Regoli D., Boudon A., Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46(4):1994;551-599
47. 3 receptor involvement in anxiety. Neuropeptides. 33:1999;181-188
48. Rodgers R.J., Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci. Biobehav. Rev. 21(6):1997;801-810
49. Rodgers R.J., Cao B.J., Dalvi A., Holmes A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30(3):1997;289-304
50. Roske I., Oehme P., Hecht K., Nieber K., Hilse H., Wachtel E. The role of the N-terminal of the substance P molecule in its action in stress-related behavioral and blood pressure disorders. Pharmazie. 41:1986;799-805
51. 1) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology. 39:2000;1413-1421
52. Sakurada T., Le Greves P., Stewart J., Terenius L. Measurement of substance P metabolites in rat CNS. J. Neurochem. 44(3):1985;718-722
53. Sakurada T., Tan-No K., Yamada T., Sakurada S., Kisara K. Phosphoramidon potentiates mammalian tachykinin-induced biting. Pharmacol. Biochem. Behav. 37(4):1990;779-783
54. Sakurada C., Watanabe C., Sakurada S., Tan-No K., Sakurada T. Major metabolites of substance P degraded by spinal synaptic membranes antagonize the behavioral response to substance P in rats. J. Pharm. Sci. 88(11):1999;1127-1132
55. Santarelli L., Gobbi G., Debs P.C., Sibille E.T., Blier P., Hen R., et al. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. U.S.A. 98(4):2001;1912-1917
56. 1 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol. 375:1999;51-60
57. Strittmatter M., Isenberg E., Grauer M.T., Hamann G., Schimrigk K. CSF substance P somatostatin and monoaminergic transmitter metabolites in patients with narcolepsy. Neurosci. Lett. 218(2):1996;99-102
58. Teixeira R.M., Santos A.R.S., Ribeiro S.J., Calixto J.B., Rae G.A., De Lima T.C.M. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 311:1996;7-14
59. 3 receptors in the prefrontal cortex of the human brain. Clin. Exp. Pharmacol. Physiol. 27(11):2000;947-949
60. Tschöpe C., Jost N., Unger T., Culman J. Central cardiovascular and behavioral effects of carboxy- and amino-terminal fragments of substance P in conscious rats. Brain Res. 690:1995;15-24
61. Von Euler U.S., Gaddum J.H. An unidentified depressor in certain tissue extracts. J. Physiol. 72:1931;74-87
62. Wall P.M., Messier C. Ethological confirmatory factor analysis of anxiety-like behaviour in the murine elevated plus-maze. Behav. Brain Res. 114:2000;199-212
63. Wang L., Sadoun E., Stephens R.E., Ward P.E. Metabolism of substance P and neurokinin A by human vascular endothelium and smooth muscle. Peptides. 15(3):1994;497-503
64. Whelpton R., Michael-Titus A.T., Stephens S.M., Yau K.W., Fengas D. Identification of substance P metabolites using a combination of reversed-phase high-performance liquid chromatography and capillary electrophoresis. J. Chromatogr. B Biomed. Sci. Appl. 716(1/2):1998;95-106
65. Williams T.A., Hooper N.M., Turner A.J. Characterization of neuronal and endothelial forms of angiotensin converting enzyme in pig brain. J. Neurochem. 57:1991;193-199
66. Yip J., Chahl L.A. Distribution of Fos-like immunoreactivity in guinea-pig brain following administration of the neurokinin-1 receptor agonist, [SAR9,MET(O2)11]substance P. Neuroscience. 94(2):1999;663-673